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Thrombocytopenia is a common hematologic abnormality during pregnancy. It may be a diagnostic and management 
problem, and has many causes, some of them specific to pregnancy. We considered all singleton deliveries after 24 weeks 
of gestation between 2007 and 2012 in our third level centre. Women with a platelet count <100 × 109/L, but who did not 
suffer from the aforementioned diseases, were considered to have incidental thrombocytopenia. The aim of this study is to 
investigate the incidences of moderate and severe gestational thrombocytopenia, to determine if the severity of maternal 
gestational thrombocytopenia affect perinatal outcome and to define if the severity of maternal gestational thrombocytope-
nia implicates the appearance of neonatal thrombocytopenia.
VESNA ELVE\I GAŠPAROVIĆ (  ) •
PETRANA BELJAN •
SNJEŽANA ŠKRABLIN
Department of Obstetrics and Gynecology
University Hospital Centre Zagreb, Zagreb




Department of Obstetrics and Gynaecology
Neonatal Intensive Care Unit 
University Hospital Centre Zagreb 
Zagreb, Croatia
VESNA ELVE\I GAŠPAROVIĆ • SNJEŽANA GVERIĆ AHMETAŠEVIĆ • 
PETRANA BELJAN • SNJEŽANA ŠKRABLIN
   SIGNA VITAE 2014; 9 (Suppl 1): 49 - 53
Key words: gestational thrombocyto-
penia, neonatal thrombocytopenia 
Introduction
Thrombocytopenia, defined as a platelet 
count of <150 × 109/L, is a common 
hematologic abnormality during pre-
gnancy, with an incidence of 6.6%. (1) 
When thrombocytopenia is detected 
during pregnancy, it may be related to a 
pre-existing underlying disease, such as 
bone marrow disease, hypersplenism, 
or congenital platelet disorder. It may 
also be a sign of complex clinical disor-
ders that are unique to pregnancy, such 
as preeclampsia and hemolysis, eleva-
ted liver enzymes, and low platelet count 
(HELLP) syndrome. Furthermore, auto-
immune diseases, including systemic 
lupus erythematosus, antiphospholipid 
syndrome, thrombotic thrombocytope-
nic purpura, hemolytic uremic syndro-
me, and immune thrombocytopenia 
(ITP) may relapse or be first detected 
during pregnancy. Nevertheless, the 
most common cause of pregnancy-
related thrombocytopenia is gestational 
thrombocytopenia, which is diagnosed 
through exclusion when the postpartum 
platelet count returns to normal and is 
usually associated with an uneventful 
pregnancy outcome. Gestational throm-
bocytopenia (GT) is considered the most 
prevalent cause of thrombocytopenia in 
pregnancy and accounts for about 75% 
of cases of thrombocytopenia during 
pregnancy. (2) It is defined by a platelet 
count of no less than 70 × 109/L, espe-
cially during the third trimester, and the 
count returns to normal within 12 weeks 
of delivery. (3) The etiology is unknown, 
but is considered to be due to the relati-
ve hemodilution in pregnancy, amplified 
by the capture or destruction of platelets 
in the placenta. (4) Most existing studies 
have addressed a specific etiology of 
thrombocytopenia in pregnant women, 
but only a few have compared different 
etiologies, all using a platelet count of 
150 × 109/L as the reference value. 
(5-9) Since it is widely accepted that the 
prognosis of mild thrombocytopenia (a 
platelet count above 100,000, generally 
caused by GT) is acceptable and with 
no major complications, we focused on 
moderate to severe thrombocytopenia. 
The present study was aimed to inve-
stigate the incidence of moderate and 
severe gestational thrombocytopenia, 
to determine if the severity of mater-
nal gestational thrombocytopenia affect 
perinatal outcome and to define if the 
severity of maternal gestational throm-
bocytopenia implicates the appearance 
of neonatal thrombocytopenia.
Materials and methods
We considered all singleton deliveries 
after 24 weeks of gestation between 
2007 and 2012 in our third level centre. 
Patients were excluded from the study 
if they suffered from chronic hyperten-
sion, diabetes mellitus, liver diseases 
(acute hepatitis, acute fatty liver, and/
or liver cirrhosis), renal diseases and 
autoimmune disorders such as systemic 
lupus erythematosus and ITP. Pregnan-
cies complicated with fetal structural or 
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chromosomal anomalies and gestati-
onal hypertensive diseases, including 
preeclampsia, eclampsia, and HELLP 
syndrome, were also excluded. Women 
with a platelet count <100 × 109/L, but 
who did not suffer from the aforementio-
ned diseases, were considered to have 
incidental thrombocytopenia. These 
individuals were divided into two groups 
according to the platelet count: Group 1 
(“Severe group”, severe thrombocyto-
penia) with a platelet count <50 × 109/L 
and Group 2 (“Moderate group”, mode-
rate thrombocytopenia) with a platelet 
count 50–100 × 109/L.
We studied the following perinatal outco-
mes: type of delivery, placental abrupti-
on, severe postpartum bleeding, peri-
partal hysterectomy, birth weight, fetal 
death, 1 minute and 5 minute Apgar 
scores <7, premature delivery, perinatal 
infection, neonatal thrombocytopenia, 
admission to the neonatal intensive care 
unit and neonatal death.
The following maternal characteristi-
cs were factors that were evaluated in 
assessing potential confounding factors 
in the relationship between maternal 
platelet count and pregnancy outcome: 
age of mother, gestational age, parity, 
method of conception (natural or assi-
sted reproductive technology), previous 
abortions, thrombocytopenia in previous 
pregnancies and fetal death in previous 
pregnancies, use of corticosteroides 
and transfusions with packed platelet 
cells. Statistical analysis was performed 
using SPSS version 20 (SPSS Inc., Chi-
cago, IL, USA). Nominal variables were 
expressed by count and percentage. 
Nominal variables were analyzed using 
Chi-square tests or Fisher’s exact test. 
All measurement variables had nonpa-
rametric distribution and were expre-
ssed by a median. A p value of <0.05 
was considered statistically significant.
Results 
There were 80 pregnancies which ful-
filled the inclusion criteria for our study 
for idiopathic (gestational) thrombo-
cytopenia. 67 patients (79%) had a 
platelet count of 50-100 × 109/L, and 
only 17 (21%) had a platelet count <50 
×109/L. Thrombocytopenia in previous 
pregnancy seems to be an important 
factor for severe thrombocytopenia in 
present pregnancy (p=0.029).
We found a significant difference in the 
need for corticosteroid therapy and pac-
ked platelet cells transfusion between 
the groups; 8 patients (8%) from the 
Moderate group and 7 patients (41%) 
from the Severe group received cortico-
steroid therapy (p=0.008). Two patients 
from the Severe group (11.76%) and one 
from the Moderate group (1.59%) were 
transfused with packed platelet cells 
during the pregnancy (p=0.05).
We found no difference in severity of 
maternal thrombocytopenia regarding 
the method of conception, maternal 
age, parity, history of previous abortion 
and fetal death. Two newborns (12%) 
from mothers with severe thrombocyto-
penia had neonatal thrombocytopenia, 
and one of them was admitted to the 
Neonatal Intensive Care Unit (NICU). 
Only one newborn from a mother with 
moderate thrombocytopenia had neo-
natal thrombocytopenia, what is signifi-
cantly different (p=0.05). The newborns 
platelet count returned to normal within 
seven days without any treatment. A 
vaginal delivery was carried out in 43 
patients (68%) with moderate throm-
bocytopenia and 9 patients (53%) with 
severe thrombocytopenia. 20 (32%) 
patients from the Moderate group and 
8 patients (47%) from the Severe group 
underwent caesarean section due to 
obstetric indications.
Neonatal bleeding, disseminate intra-
vascular coagulation, severe maternal 
postpartum bleeding and peripartal 
hysterectomy did not occur in any of 
our patients. There were no neonatal 
deaths.
We found no difference between the 
groups in Apgar score, perinatal infecti-
on and preterm delivery rate.  We found 
no statistically significant difference 
between the mode of delivery and seve-
rity of maternal gestational thrombo-
cytopenia (p=0.240). 
Table 1. Comparison of maternal characteristics 
Variables
M o d e r a t e  g r o u p 
(n = 63)
Severe  group 
(n = 17)
P
Age (year) 30 (19–44) 29 (21–41) 0.763
Gestational age (week) 39 (33–42) 39 (36–41) 0.345
Platelet count (× 109/L) 82 (51-98) 37 (7-49) 0.001
Primiparity 29 (46.03%) 8 (47.05%) 0.940
Thrombocytopenia in previ-
ous pregnancy
2 (3.17%) 3 (17.65%)     0.029
Conception after assisted 
reproductive technology
2 (3.17%) 2 (11.76%) 0.146
Previous history of abortion 16 (25.40%) 1 (5.88%) 0.081
Previous history of fetal 
death 1 (1.59%) 1 (5.88%) 0.314
Corticosteroid therapy in this 
pregnancy 8 (12.70%) 7 (41.18%)        0.008
Transfused with packed 
platelet cells
1 (1.59%)                          2 (11.76%)   0.05
Data are expressed as median or n (%)
Moderate group: platelet count 50-100 × 109/L
Severe group: platelet count <50 × 109/L
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We reported one placental abruption 
in the Moderate group with no serious 
effects for the mother or the infant. 
Discussion
Thrombocytopenia occurring during 
pregnancy is a common diagnostic and 
management problem and may have 
many causes. (10) Platelet counts are wit-
hin the normal range of 150-450 × 109/L 
in the vast majority of women during 
normal pregnancies, however they may 
be slightly lower, on average, than in 
healthy, non-pregnant women. (7) The 
frequency of gestational thrombocyto-
penia in the largest series of consecutive 
women admitted for labour and delivery 
is 5%. (11) In this series, neonatal throm-
bocytopenia did not occur in infants 
born to mothers with gestational throm-
bocytopenia. In our study, cumulative 
incidence of gestational thrombocyto-
penia was 0.46% (the incidence rate was 
1.83 cases per 1,000 persons per year). 
Within the group of gestational throm-
bocytopenia, we found 17 cases (21%) 
of severe thrombocytopenia, which is 
about 0.1% of all singleton deliveries in 
a 5 year period in our hospital, which is 
similar to Karim et al. who documented 
incidence of severe thrombocytopenia 
in less than 0.1%pregnancies. (10) This 
variance might be due to our exclusion 
of women with major systemic diseases, 
as well as those with gestational hyper-
tensive diseases.
In our study, women with thrombocyto-
penia generally had a higher rate of 
caesarean delivery than women with a 
normal platelet count, but with no diffe-
rence within the study groups (p=0.24) 
(table 2). Thrombocytopenia is not usu-
ally considered an indication of caesa-
rean delivery, and most previous stu-
dies have preferred vaginal delivery as 
long as no other obstetric indications 
were present. 
Nevertheless, clinicians may still be 
concerned about obstetric complica-
tions, such as vaginal hematoma or 
vaginal wall laceration, which can lead 
to uncontrolled bleeding when exacer-
bated by thrombocytopenia. Therefore, 
when thrombocytopenic women pre-
sent signs of abnormal labour, clinici-
ans may aggressively suggest a cae-
sarean section, which will increases the 
incidence. However, our results shows 
that women who had thrombocytope-
nia at vaginal delivery, but did not suffer 
from any other medical diseases, had 
favourable perinatal outcome. 
In one pregnancy complicated with pla-
cental abruption we found no dissemi-
nated intravascular coagulation or intra-
uterine fetal death, the mother had a 
Table 2. Maternal, fetal and neonatal outcome
 Moderate group (n =63) Severe group (n = 17) P
Postpartum haemorrhage 0 0 1.000
Disseminated intravascular coagulopathy 0 0 1.000
Placental abruption 1 (1.59%) 0 0.601
Caesarean section 20 (31.74%) 8 (47.06%) 0.240
Peripartum hysterectomy 0 0 1.000
Vaginal delivery 43 (68.25%)                        9 (52.94%) 0.240
Birth weight (g) 3280 (1820–4480) 3260 (2250–4300) 0.345
Fetal death 0 0 1.000
Preterm delivery 5 (7.94%)                              2 (11.76%) 0.620
1-min Apgar score <7 2 (3.17%) 0 0.457
5-min Apgar score <7 0 0 1.000
Admission to NICU 0 1 (5.88%) 0.053




Data are expressed as median or n (%)
Moderate group: platelet count 50-100 × 109/L
Severe group: platelet count <50 × 109/L
NICU, neonatal intensive care unit
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platelet count of 85 × 109/L. This case 
suggests that clinicians should exclude 
occult placental abruption and acute 
blood loss when investigating the cause 
of severe thrombocytopenia in women 
with no major medical disease or gesta-
tional hypertensive disorder. However, 
the risk of postpartum haemorrhage, 
hysterectomy, disseminated intravas-
cular coagulation, placental abruption, 
mode of delivery and Apgar score in 
women with gestational thrombocyto-
penia was no different when comparing 
the severity of maternal illness (table 
2). Some investigators, such as Par-
nas et al., observed that patients with 
moderate to severe thrombocytopenia 
have higher rates of preterm deliveries 
(<37 weeks). (11) Our study found no 
significant difference between preterm 
delivery rates (p=0.285) (table 2).
One of our objectives was to determi-
ne the relationship between severity 
of gestational thrombocytopenia and 
neonatal outcome.
Some authors associate thrombocyto-
penia with adverse neonatal outcome. 
(1,10,11) We found neonatal thrombo-
cytopenia in 12% of cases in the Severe 
maternal thrombocytopenia group – a 
significantly higher rate when compa-
red to the Moderate group (p=0.050) 
(table 2). The immediate concern is for 
fetal thrombocytopenia and the resulting 
risk for intracranial haemorrhage after 
delivery. A large case series suggests 
that there is no risk. (12) However, a few 
smaller case series of selected women 
with severe thrombocytopenia and their 
newborns had thrombocytopenia too. 
Ruggeri’s report of 41 pregnancies with 
gestational thrombocytopenia reported 
two newborns with mild thrombocyto-
penia and one with severe thrombo-
cytopenia. (13) Our study confirmed 
that most cases of severe gestational 
thrombocytopenia have an uncomplica-
ted course, with no significant maternal 
or fetal morbidity, even in the extreme 
situation we had with our patient with a 
platelet count of 7 × 109/L.
Gestational thrombocytopenia is a 
benign condition, usually detected inci-
dentally during the third trimester and 
presents no risk of increased bleeding 
to the mother. The risk of thrombo-
cytopenia in neonates born to mothers 
with gestational thrombocytopenia is 
also considered insignificant. (14-16) 
Although the etiology of this condition 
is unknown, many features of gestati-
onal thrombocytopenia are similar to 
those of mild immune thrombocyto-
penia. Moreover, several observations 
support the hypothesis that gestational 
thrombocytopenia may be a mild and 
transient form of immune thrombocyto-
penia. (17,18)
There is no consistent correlation 
between appearance of neonatal 
thrombocytopenia and the severity of 
maternal thrombocytopenia. (14,15,16) 
According to previous studies, the best 
predictor of neonatal thrombocytope-
nia is a history of thrombocytopenia in 
a prior sibling. (17) Our data also shows 
that thrombocytopenia in a previous 
pregnancy seems to be an important 
factor for severe thrombocytopenia in a 
present pregnancy (p=0.029) (table1).
The neonatal platelet count often does 
not correlate with the maternal plate-
let count, and treatment of the mother 
with glucocorticoids does not alter the 
incidence of fetal thrombocytopenia. 
(18,19) Our study reported statistically 
frequent use of glucocorticoids in the 
Severe group (p=0.008) (table1). Des-
pite this, we found that two newborns 
from mothers with severe thrombocyto-
penia had neonatal thrombocytopenia 
and one of them was admitted to the 
Neonatal Intensive Care Unit (NICU). 
Only one newborn from a mother with 
moderate thrombocytopenia had neo-
natal thrombocytopenia, what is signifi-
cantly different (p=0.05)(table2).
According to this study, pregnancies 
with severe gestational thrombocyto-
penia do not face an increased risk 
of intrapartal fetal distress, caesarean 
section rate, intrauterine fetal death, 
preterm delivery, low Apgar scores, 
increased admission rate to the neona-
tal intensive care unit, intracranial hae-
morrhage, neonatal death or adverse 
maternal outcome.
Conclusion
Our results suggest that the appearance 
of severe gestational thrombocytopenia 
is more frequent in patients with throm-
bocytopenia in a previous pregnancy 
and that the appearance of neonatal 
thrombocytopenia is more likely from 
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